
|Videos|October 20, 2016
High Cost Drug Launches and Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
4
Bringing Bispecific Therapy Into the Outpatient Community Oncology Setting
5






































































































